Prospect:Information for the User
Paricalcitol Accordpharma 2 micrograms/ml Injectable SolutionEFG
Read this prospect carefully before starting to use this medication, as it contains important information for you.
1.What is Paricalcitol Accordpharma and how is it used
2.What you need to know before starting to use Paricalcitol Accordpharma
3.How to use Paricalcitol Accordpharma
4.Possible adverse effects
5Storage of Paricalcitol Accordpharma
6.Contents of the package and additional information
Paricalcitol Accordpharma is a synthetic analog of activated vitamin D, which is required for the normal functioning of many tissues in the body, including the parathyroid gland and bones. In people with normal renal function, this active form of vitamin D is naturally produced by the kidneys, but in renal insufficiency, the production of active vitamin D is significantly reduced. Therefore, paricalcitol provides a source of active vitamin D when the body cannot produce enough and helps to prevent the consequences of low levels of active vitamin D in patients with chronic kidney disease, specifically with high levels of parathyroid hormone that can cause bone problems. Paricalcitol is indicated in adult patients with stage 5 chronic kidney disease.
Do not use Paricalcitol Accordpharma:
Your doctor will monitor your blood levels and can tell you if these conditions apply to you.
Warnings and precautions
Consult your doctor or nurse before starting to use Paricalcitol Accordpharma.
Use of Paricalcitol Accordpharma with other medications
Inform your doctor, nurse, or pharmacist if you are using, have used recently, or may need to use any other medication.
Some medications may affect the action of paricalcitol or increase the risk of adverse effects. It is particularly important to inform your doctor if you are using any of the following medications:
Consult your doctor, nurse, or pharmacist before taking any medication.
Use of Paricalcitol Accordpharma with food and drinks
Paricalcitol can be administered with or without food.
Pregnancy and lactation
If you are pregnant or breastfeeding, consult your doctor or pharmacist before using this medication.
The safety of this medication for pregnant or breastfeeding women is unknown. Therefore, it should only be used after consulting with your doctor, who will help you make the decision that is best for you.
It is not known if paricalcitol passes into human breast milk. Inform your doctor before breastfeeding while using Paricalcitol Accordpharma.
Driving and operating machinery
During treatment with paricalcitol, your ability to drive safely or use heavy machinery may be affected.
Paricalcitol may make you feel dizzy, weak, and/or drowsy.
Do not drive or use machinery if you have these symptoms.
Important information about some of the components of Paricalcitol Accordpharma
This medication contains 157.8 mg of alcohol (ethanol) in each ml (which is equivalent to 20% in V/V).
At maximum dose of 40 mg:
It is unlikely that the amount of alcohol contained in this medication will have any noticeable effect on adults or adolescents. It may have some effects on young children, such as drowsiness.
The amount of alcohol contained in this medication may alter the effect of other medications. Consult your doctor or pharmacist if you are taking other medications.
If you are pregnant or breastfeeding, consult your doctor or pharmacist before being administered this medication. This medication is harmful to people with alcoholism.
If you have a history of alcohol addiction, consult your doctor or pharmacist before being administered this medication.
Your doctor will use the results of laboratory tests to determine the initial appropriate dose for you. Once you have started treatment with paricalcitol, the dose must be adjusted, based on the results of routine laboratory tests. Using the results of your tests, your doctor will help you determine the appropriate dose of this medication for you.
Paricalcitol will be administered by the doctor or nurse while you are being treated with the kidney machine.It will be administered through the tube that connects you to the machine. You will not need to receive an injection since this medication can be introduced directly into the tube that is being used for your treatment. You will not be receiving paricalcitol more frequently than every other day and no more than 3 times a week.
Ifyou use more Paricalcitol Accordpharma than you should
A high dose of paricalcitol can produce abnormally high levels of calcium in the blood, which can be harmful.The symptoms that may appear shortly after taking too much paricalcitol may include:
If you experience high levels of calcium in the blood after using paricalcitol, your doctor will prescribe the appropriate treatment to return your calcium levels to normal. Once your calcium levels return to normal, it is likely that you will be administered low doses of this medication.
Your doctor will monitor your blood levels. If you experience any of the symptoms mentioned above, seek medical advice immediately.
The symptoms that may appear after a long period of receiving too much paricalcitol are:
If you experience high levels of calcium in the blood after using paricalcitol, your doctor will prescribe the appropriate treatment to return your calcium levels to normal. Once your calcium levels return to normal, it is likely that you will be administered low doses of this medication.
In case of overdose or accidental ingestion, go immediately to a medical center or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
Several allergic reactions have been reported with Paricalcitol Accordpharma.Important: If you notice any of the following side effects, inform your doctor or nurse immediately:
Inform your doctor or nurse if you notice any of the following side effects:
Frequent (may affect up to 1 in 10 people) are:
Rare (may affect up to 1 in 100 people) are:
Unknown frequency(cannot be estimated from available data):
If you notice these symptoms, seek medical help immediately.
You may not identify these side effects unless your doctor has previously informed you.
If you consider any of the side effects you are experiencing to be severe or if you notice any side effects not mentioned in this prospectus, inform your doctor, nurse, or pharmacist immediately.
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keepthis medicationout of the sight and reach of children.
Store the ampoules in the outer packaging to protect from light.
Paricalcitol Accordpharma must be used immediately after opening.
Do not usethis medicationafter the expiration date that appears onthe packagingafter CAD. The expiration date is the last day of the month indicated.
Do not usethis medicationif you observe particles or discoloration.
Medications should not be disposed of through drains or trash. Ask your pharmacisthow to dispose ofthepackaging and themedications that you no longerneed. This will help protect the environment.
Composition of Paricalcitol Accordpharma
Aspect of the product and content of the package
Paricalcitol Accordpharma is a clear and colorless aqueous solution, free of visible particles. It is presented in packages with 5 ampoules of 1 ml.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Accord Healthcare S.L.U.
World Trade Center. Moll de Barcelona, s/n, Edifici Est, 6th floor.
08039, Barcelona (Spain)
Responsible for manufacturing
Pharmaten, S.A
Dervenakion 6
15351 Pallini Attiki
GREECE
Last review date of thisleaflet:June 2023
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
<------------------------------------------------------------------------------------------------------------------------->
This information is intended solely for healthcare professionals:
Instructions for the healthcare professional
Paricalcitol Accordpharma 2 micrograms/ml injectable solution
Preparation for injectable solution
Paricalcitol Accordpharma 2 micrograms/ml injectable solution is for single use. As with other parenteral medications, observe the solution for visible particles and color before administration.
Compatibility
This medication should not be mixed with other medications.
Storage and expiration
Parenteral products should be inspected before administration for the presence of visible particles and color. The solution is clear and colorless.
Store the ampoules in the outer packaging to protect from light.
Thismedicine has an expiration date of 2 years.
Dosage and administration
Paricalcitol Accordpharma injectable solution is administered through the dialysis access.
Adults
1)The initial dose should be calculated based on the baseline levels of the parathyroid hormone (PTH)
The initial dose of paricalcitol is based on the following formula:
Dose initial (micrograms) = | baseline level of intact PTH in pmol/l |
8 |
or
The maximum safe dose administered in clinical studies was 40 micrograms. 2)Dose adjustment Currently accepted levels for the PTH range in patients with terminal renal failure undergoing dialysis is not more than 1.5to 3 times the upper normal non-uremic limit, 15.9 to 31.8 pmol/l (150-300 pg/ml), for intact PTH. To achieve the desired levels of physiological variables, individualized dose adjustment and monitoring are necessary. If hypercalcemia or a corrected Ca x P product, elevated persistently, greater than 5.2 mmol2/l2(65 mg2/dl2), is observed, the dose should be reduced or discontinued until these parameters normalize.
The following table is suggested as an approximation for dose adjustment: | ||||
Guideline suggested dose (dose adjustment in intervals of 2 to 4 weeks) | |
PTHi level in relation to the baseline level | Adjustment of paricalcitol dose |
Equal to or greater than | Increase by 2 to 4 micrograms |
Decrease <30% | |
Decrease = 30% and = 60% | Maintain |
Decrease > 60% | Decrease by 2 to 4 micrograms |
PTHi <15.9 pmol/l (150 pg/mL) |
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.